First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors
Kristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, Eva Muñoz-Couselo, Andrés Cervantes, Valentina Gambardella, Laurent Greillier, Pilar Garrido, Hye Ryun Kim, Dae Ho Lee, Antoine Italiano, Philippe Alexandre Cassier, Sandrine Hiret, Sanjeev Deva, Tae Min Kim, George R Blumenschein, Rikke Løvendahl Eefsen, Brian S Henick, Mario Perro, Pablo Umaña, Antonio Peixoto, Laura Lauener, Patrick Weber, Stefan Seeber, Christian Klein, Brian Higgins, Micol Guidi, Dominik Kraus, Merlind Mücke, Christian Heichinger, Vu-Long Tran, Daniela Schmid, Francesca Michielin, Ting Liu, Christine McIntyre, Henry Kao, Laura Codarri Deak, Christoph Markert, Victor Moreno · 2026
Read First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors by Kristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, Eva Muñoz-Couselo, Andrés Cervantes, Valentina Gambardella, Laurent Greillier, Pilar Garrido, Hye Ryun Kim, Dae Ho Lee, Antoine Italiano, Philippe Alexandre Cassier, Sandrine Hiret, Sanjeev Deva, Tae Min Kim, George R Blumenschein, Rikke Løvendahl Eefsen, Brian S Henick, Mario Perro, Pablo Umaña, Antonio Peixoto, Laura Lauener, Patrick Weber, Stefan Seeber, Christian Klein, Brian Higgins, Micol Guidi, Dominik Kraus, Merlind Mücke, Christian Heichinger, Vu-Long Tran, Daniela Schmid, Francesca Michielin, Ting Liu, Christine McIntyre, Henry Kao, Laura Codarri Deak, Christoph Markert, Victor Moreno (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13289304.txt.
Description
Kristoffer Staal Rohrberg led a 2026 first-in-human study of lomvastomig, a bispecific antibody for advanced solid tumors. The drug blocks two immune brakes at once, PD-1 and TIM-3, and was built to leave other antibody functions quiet. Lab and mouse work came first, then a phase 1 trial across many centers.
Dose escalation enrolled people with advanced or spread tumors, followed by expansion groups in four tumor types. Groups included melanoma and lung cancer after prior checkpoint drugs, plus small cell lung cancer and esophageal cancer without prior checkpoint care. Goals covered safety, highest tolerated dose, drug levels, target coverage, and early tumor shrinkage. Early human data like this set the dose and tumor types for larger trials.
Catalog record
| CREATOR | Kristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, Eva Muñoz-Couselo, Andrés Cervantes, Valentina Gambardella, Laurent Greillier, Pilar Garrido, Hye Ryun Kim, Dae Ho Lee, Antoine Italiano, Philippe Alexandre Cassier, Sandrine Hiret, Sanjeev Deva, Tae Min Kim, George R Blumenschein, Rikke Løvendahl Eefsen, Brian S Henick, Mario Perro, Pablo Umaña, Antonio Peixoto, Laura Lauener, Patrick Weber, Stefan Seeber, Christian Klein, Brian Higgins, Micol Guidi, Dominik Kraus, Merlind Mücke, Christian Heichinger, Vu-Long Tran, Daniela Schmid, Francesca Michielin, Ting Liu, Christine McIntyre, Henry Kao, Laura Codarri Deak, Christoph Markert, Victor Moreno |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57550 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |